NewsShalby Limited Schedules Earnings Conference Call to Discuss Q4FY26 Results on May 29, 2026Shalby Limited Schedules Earnings Conference Call to Discuss Q4FY26 Results on May 29, 2026
Shalby Limited has scheduled an Earnings Conference Call for Friday, May 29, 2026, at 5:00 PM IST, to discuss Q4 FY2026 earnings, in compliance with Regulation 30 of SEBI LODR Regulations, 2015. The call, hosted by Elara Securities (India) Private Limited, will be attended by senior leadership including the Chairman and Managing Director, CFO, and other key executives. Dial-in access is available across multiple geographies, including toll-free numbers for the US, UK, Singapore, Hong Kong, and Australia. The disclosure was filed with both NSE and BSE on May 18, 2026.
*this image is generated using AI for illustrative purposes only.
Shalby Limited has announced an Earnings Conference Call to discuss its Q4 FY2026 financial results. The announcement, made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was communicated to both the National Stock Exchange of India Ltd and BSE Limited on May 18, 2026. The conference call is scheduled for Friday, May 29, 2026, at 5:00 PM IST, and will be hosted by Elara Securities (India) Private Limited.
Senior Leadership to Represent the Company
The earnings call will feature a distinguished panel of senior executives from Shalby Limited. The key representatives scheduled to participate are outlined below:
| Role | Representative |
|---|---|
| Chairman and Managing Director | Dr. Vikram Shah |
| President | Mr. Shanay Shah |
| COO, Shalby Hospitals | Dr. Nishita Shukla |
| CEO, Shalby MedTech | Mr. Deepak Anand |
| CFO | Mr. Amit Kumar |
| CHRO | Mr. Babu Thomas |
| IRCS | Mr. Jigar Todi |
Conference Call Access Details
Participants can join the call through multiple dial-in options across geographies. The following access numbers have been provided:
| Region | Dial-In Number |
|---|---|
| Universal (India) | +91 22 6280 1146 |
| Universal (India) | +91 22 7115 8047 |
| Toll Free – US | 1 866 746 2133 |
| Toll Free – UK | 0 808 101 1573 |
| Toll Free – Singapore | 800 101 2045 |
| Toll Free – Hong Kong | 800 964 448 |
| Toll Free – Australia | 0080014243444 |
The call timings across key international time zones are as follows:
- 12:30 PM – United Kingdom
- 7:30 PM – Singapore and Hong Kong
- 7:30 AM – East Coast, US
- 4:30 AM – West Coast, US
Participants may also register via the Diamond Pass Login link provided in the official invite. For RSVPs and further queries, participants can contact Dr. Bino Pathiparampil at Elara Capital via email at bino.pathiparampil@elaracapital.com or by phone at +91 22 6164 8689.
Regulatory Compliance
The disclosure was signed by Tushar Shah, Vice President & Company Secretary (Membership No. F7216), on behalf of Shalby Limited. The communication was submitted to both stock exchanges in accordance with applicable SEBI listing regulations, affirming the company's adherence to its disclosure obligations.
Historical Stock Returns for Shalby
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.45% | -0.39% | +2.35% | -26.39% | -17.15% | +4.11% |
What key financial metrics and guidance for FY2027 is Shalby Limited expected to reveal during the Q4 FY2026 earnings call?
How might Shalby MedTech's performance in Q4 FY2026 signal the company's strategic pivot toward medical technology and its contribution to future revenue diversification?
Given the presence of both hospital operations (COO) and MedTech (CEO) leadership on the call, could Shalby be planning a structural reorganization or separate listing of its MedTech division?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
